Phase 3 Readout
BYSI: Phase 3 Topline: A Global, Multicenter, Randomized, Double-blinded, Phase 3 Study of Docetaxel + Plinabulin Compared
December 1, 2029 · docetaxel. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- December 1, 2029
- Company
- BeyondSpring Inc. (BYSI)
- Drug
- docetaxel
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Global, Multicenter, Randomized, Double-blinded, Phase 3 Study of Docetaxel + Plinabulin Compared
- Company
- BeyondSpring Inc. (BYSI)
- Drug
- docetaxel
- Indication
- Non-Small Cell Lung Cancer; Non-squamous Non-Small Cell Lung Cance